BCI is a small-molecule that acts as a dual-inhibitor of DUSP1 and DUSP6, exerting anti-tumorigenic activity in a wide range of cancer models (Figure 1A) (Kaltenmeier et al., 2017; Wu et al., 2018; James et al., 2019; Ramkissoon et al., 2019; Duan et al., 2021; Nair et al., 2021; Singh et al., 2022). Here, DUSP1 is linked to cancer.